An Observational, multicentre, open label, non interventional programme to assess the long-term safety and efficacy of Somatuline® Autogel® in the treatment of neuroendocrine tumours when administered by patients or their partners (“Home Injection Group”) or administered by Healthcare Professionals (Somatuline NET PMS 215 study)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  Prospective patient-based data collection

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown